EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ewing sarcoma from molecular biology to the clinic

Maryne Dupuy, François Lamoureux, Mathilde Mullard, Anaïs Postec, Laura Regnier, Marc Baud'huin, Steven Georges, Bénédicte Brounais-Le Royer, Benjamin Ory, Françoise Rédini, Franck Verrecchia

Frontiers in Cell and Developmental Biology · 11.09.2023 · 11

DOI: 10.3389/fcell.2023.1248753 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 11.09.2023. Verfasst von Maryne Dupuy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, Inserm UMR 1307, CNRS UMR 6075, CRCI2NA, Université d'Angers, Nantes, France. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Europe, with an incidence of 7.5 cases per million, Ewing sarcoma (ES) is the second most common primary malignant bone tumor in children, adolescents and young adults, after osteosarcoma. Since the 1980s, conventional treatment has been based on the use of neoadjuvant and adjuvant chemotherapeutic agents combined with surgical resection of the tumor when possible. These treatments have increased the patient survival rate to 70% for localized forms, which drops drastically to less than 30% when patients are resistant to chemotherapy or when pulmonary metastases are present at diagnosis. However, the lack of improvement in these survival rates over the last decades points to the urgent need for new therapies. Genetically, ES is characterized by a chromosomal translocation between a member of the FET family and a member of the ETS family. In 85% of cases, the chromosomal translocation found is (11; 22) (q24; q12), between the EWS RNA-binding protein and the FLI1 transcription factor, leading to the EWS-FLI1 fusion protein. This chimeric protein acts as an oncogenic factor playing a crucial role in the development of ES. This review provides a non-exhaustive overview of ES from a clinical and biological point of view, describing its main clinical, cellular and molecular aspects.

Schlagwörter

Stichwörter der Autor:innen

EWS-FLI1cellular biologyclinicalewing sarcomamolecular biology

Autor:innen und Institutionen

  • Nantes Université, Inserm UMR 1307, CNRS UMR 6075, CRCI2NA, Université d'Angers, Nantes, France.

Zitieren

APA

Dupuy, M., Lamoureux, F., Mullard, M., Postec, A., Regnier, L., Baud'huin, M., Georges, S., Brounais-Le Royer, B., Ory, B., Rédini, F., & Verrecchia, F. (2023). Ewing sarcoma from molecular biology to the clinic. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1248753

Vancouver

Dupuy M, Lamoureux F, Mullard M, Postec A, Regnier L, Baud'huin M, et al. Ewing sarcoma from molecular biology to the clinic. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1248753

BibTeX
@article{Dupuy2023,
  author = {Dupuy, Maryne and Lamoureux, François and Mullard, Mathilde and Postec, Anaïs and Regnier, Laura and Baud'huin, Marc and Georges, Steven and Brounais-Le Royer, Bénédicte and Ory, Benjamin and Rédini, Françoise and Verrecchia, Franck},
  title = {Ewing sarcoma from molecular biology to the clinic},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  volume = {11},
  doi = {10.3389/fcell.2023.1248753}
}
Kostenlos starten →